Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This prospective, single-center observational cohort study aims to explore the relationship between skeletal muscle quality, fat distribution, and metabolic health in Chinese patients with obesity, and to evaluate how bariatric surgery influences these parameters.
A total of 120 participants will be enrolled, including 60 patients undergoing bariatric surgery and 60 age- and sex-matched healthy controls. The study involves cross-sectional comparisons of ectopic fat and muscle composition, as well as longitudinal follow-up of surgical patients at multiple time points up to 5 years postoperatively.
MRI will be used to quantify regional fat and muscle composition, while metabolic parameters, inflammatory markers, and gut microbiota profiles will also be assessed. Primary outcomes include skeletal muscle mass and fat infiltration, visceral and subcutaneous fat volumes, and changes in insulin resistance.
This study seeks to clarify the mechanisms by which bariatric surgery improves metabolic function and to identify early changes in muscle-fat composition that may predict long-term metabolic outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bariatric surgery | Procedure | This is a prospective observational study evaluating the metabolic and tissue-level effects of bariatric surgery in obese individuals. The intervention includes either laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB), performed according to standard clinical guidelines. No experimental procedures are added beyond routine care. Skeletal muscle quality and visceral fat distribution are assessed using MRI and clinical biomarkers at multiple postoperative time points (baseline, 3 months, 12 months, and annually up to 5 years). A healthy control group undergoes baseline evaluation only, without surgical intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Skeletal Muscle Fat Infiltration and Quality (measured by MRI) | Quantitative evaluation of intramuscular fat content using MRI-derived proton density fat fraction (PDFF) and muscle attenuation indices in the thigh and paraspinal muscles. Muscle quality will be assessed by MRI signal intensity and texture features to detect early changes in muscle composition post-surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Change in Visceral and Subcutaneous Fat Volume (measured by MRI) | MRI-based measurement of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), liver fat percentage (LFP), and pancreatic fat percentage (PFP) to track region-specific fat redistribution after bariatric surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Change in fasting glucose | Fasting glucose to evaluate metabolic improvement after surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Change in HbA1c | HbA1c to evaluate metabolic improvement after surgery. |
Not provided
Inclusion Criteria (For Surgical Group):
Inclusion Criteria (For Healthy Control Group):
Exclusion Criteria :
Cardiac pacemaker Artificial heart valves Ferromagnetic vascular clips Metallic foreign bodies in the eye
∙Considered unsuitable for the study by investigators based on risk-benefit assessment
Not provided
Not provided
This study will enroll adult participants aged 18 to 65 years, including two groups: (1) obese patients undergoing bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass), and (2) healthy individuals with normal BMI (18.0-24.0 kg/m²) and no metabolic comorbidities. The surgical group consists of patients eligible for metabolic surgery based on national clinical guidelines. The healthy control group is matched by age and sex and will undergo only baseline assessments. All participants must be able to provide informed consent and comply with study procedures. The study population is recruited from Xiangya Third Hospital, Central South University.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xiangya Third Hospital, Central South University | Changsha | Hunan | 410013 | China |
De-identified individual participant data (IPD) related to primary and secondary outcomes (e.g., MRI measurements, metabolic indicators, and inflammatory markers) may be shared with qualified researchers upon reasonable request. Data will be made available after publication of the main results and approval by the principal investigator.
Beginning 6 months after publication of primary results; available for up to 3 years.
Requests must be accompanied by a research proposal and data use agreement. Access will be granted to researchers whose proposed use of the data has been approved by the study team.
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D050110 | Bariatric Surgery |
| ID | Term |
|---|---|
| D049088 | Bariatrics |
| D000073319 | Obesity Management |
| D013812 | Therapeutics |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline, 3 months, 12 months, annually up to 5 years |
| Change in triglycerides | Triglycerides to evaluate metabolic improvement after surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Change in LDL-C | LDL-C to evaluate metabolic improvement after surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Change in HDL-C | HDL-C to evaluate metabolic improvement after surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Change in total cholesterol | total cholesterol to evaluate metabolic improvement after surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Change in insulin resistance | HOMA-IR to evaluate metabolic improvement after surgery. | Baseline, 3 months, 12 months, annually up to 5 years |
| Change in body mass index | Body mass index (BMI), calculated as weight in kilograms divided by height in meters squared (kg/m²), will be measured at baseline and follow-up visits to assess changes in overall adiposity after bariatric surgery. BMI will be used as a general anthropometric indicator of weight loss efficacy over time. | Baseline, 3 months, 12 months annually up to 5 years |
| Change in waist circumference | Waist circumference will be measured in centimeters using a standardized tape measure at the midpoint between the lowest rib and the iliac crest. This anthropometric indicator will be used to evaluate central (abdominal) fat reduction following bariatric surgery. Measurements will be taken at baseline and at follow-up time points to assess longitudinal changes. | Baseline, 3 months, 12 months annually up to 5 years |
| Change in hip circumference | Hip circumference will be measured in centimeters at the widest portion of the buttocks using a standardized measuring tape. This anthropometric measure will help assess changes in fat distribution following bariatric surgery. Measurements will be recorded at baseline and follow-up visits to monitor longitudinal changes in body composition. | Baseline, 3 months, 12 months annually up to 5 years |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |